The Neuroblastoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Neuroblastoma Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neuroblastoma Market.
Some of the key takeaways from the Neuroblastoma Pipeline Report:
- Companies across the globe are diligently working toward developing novel Neuroblastoma treatment therapies with a considerable amount of success over the years.
- Neuroblastoma companies working in the treatment market are ORIC Pharmaceuticals, Inc., Aum Bio, NanoPharmaceuticals, Athenex, Inc., Actuate Therapeutics Inc., PersonGen BioTherapeutics, KC Pharmaceuticals, Jubilant Pharmova Limited, Recombio, Clarity Pharmaceuticals, Eli Lilly and Company, Aptorum Group, and others, are developing therapies for the Neuroblastoma treatment
- Emerging Neuroblastoma therapies in the different phases of clinical trials are- PLK4 Inhibitor Program, AUM302, BG-P-TAT, KUR-501, 9-ING-41, TAA06, DFMO (Eflornithine HCl), Iobenguane (131I), Racotumomab, 67Cu MeCOSar Octreotate, LY3295668, SACT 1, and others are expected to have a significant impact on the Neuroblastoma market in the coming years.
- In July 2022, TAA06, an engineered autologous cell therapy that targets B7-H3 for the treatment of R/R Neuroblastoma, was approved by the Centre for Drug Evaluation (CDE) of the NMPA, according to a statement released by PersonGen Biotherapeutics.
- In February 2022, According to a Clarity Pharmaceuticals announcement, the 64Cu/67Cu SARTATETM Neuroblastoma trial (CL04 trial) has finished cohort 1 and moved on to cohort 2.
- In March 2022, The US Food and Drug Administration (FDA) has designated alrizomadlin (APG-115) by Ascentage Pharma's unique MDM2-p53 inhibitor as a Rare Paediatric Disease (RPD) for the treatment of neuroblastoma.
- In May 2022, The Phase 1 clinical trial results for SACT-1, a repurposed small molecule medication that targets neuroblastoma and possibly other cancer types, were released by Aptorum Group Limited. The trial treatments were well tolerated, and no patients' participation in the study was terminated due to negative side effects. Throughout the research, there were no grave adverse events reported. Any QT interval following oral administration of SACT-1 at 150mg was likely well within clinically acceptable bounds, according to the phase 1 clinical data.
- In January 2021, KUR-501 (autologous GD2 CAR-NKT cells) is being tested in patients with relapsed/refractory (R/R) neuroblastoma, and KUR-502 (off-the-shelf CD19 CAR-NKT cells) is being tested in patients with R/R CD19 positive malignancies. Kuur Therapeutics recently announced clinical updates for both of these studies. The CAR-NKT cell therapy has been safe and well-tolerated, and both trials have seen complete responses and indications of tumour homing.
Neuroblastoma Overview
A rare form of cancer called neuroblastoma primarily affects infants and young children. It arises from specialised nerve cells (neuroblasts) that are left over from a baby's womb development.
Get a Free Sample PDF Report to know more about Neuroblastoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/neuroblastoma-pipeline-insight
Emerging Neuroblastoma Drugs Under Different Phases of Clinical Development Include:
- PLK4 Inhibitor Program: ORIC Pharmaceuticals, Inc.
- AUM302: Aum Bio
- BG-P-TAT: NanoPharmaceuticals
- KUR-501: Athenex, Inc.
- 9-ING-41: Actuate Therapeutics Inc.
- TAA06: PersonGen BioTherapeutics
- DFMO (Eflornithine HCl): KC Pharmaceuticals
- Iobenguane (131I): Jubilant Pharmova Limited
- Racotumomab: Recombio
- 67Cu MeCOSar Octreotate: Clarity Pharmaceuticals
- LY3295668: Eli Lilly and Company
- SACT 1: Aptorum Group
Neuroblastoma Route of Administration
Neuroblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Neuroblastoma Molecule Type
Neuroblastoma Products have been categorized under various Molecule types, such as
- Oligonucleotide
- Peptide
- Small molecule
Neuroblastoma Pipeline Therapeutics Assessment
- Neuroblastoma Assessment by Product Type
- Neuroblastoma By Stage and Product Type
- Neuroblastoma Assessment by Route of Administration
- Neuroblastoma By Stage and Route of Administration
- Neuroblastoma Assessment by Molecule Type
- Neuroblastoma by Stage and Molecule Type
DelveInsight's Neuroblastoma Report covers around 35+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Neuroblastoma product details are provided in the report. Download the Neuroblastoma pipeline report to learn more about the emerging Neuroblastoma therapies
Some of the key companies in the Neuroblastoma Therapeutics Market include:
Key companies developing therapies for Neuroblastoma are - Clarity Pharmaceuticals Ltd, Eli Lilly and Company, Laboratorio Elea Phoenix S.A., PersonGen BioTherapeutics (Suzhou) Co., Ltd., Advanced Accelerator Applications, K C Pharmaceuticals Inc., Curis, Inc., Pfizer, Valent Technologies, LLC, UGISense AG, Y-mAbs Therapeutics, Ascentage Pharma, Kuur Therapeutics, Cell Medica, Autolus, NanoPharmaceuticals, Aptorum Group, and others.
Neuroblastoma Pipeline Analysis:
The Neuroblastoma pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Neuroblastoma with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuroblastoma Treatment.
- Neuroblastoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Neuroblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuroblastoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Neuroblastoma drugs and therapies
Neuroblastoma Pipeline Market Drivers
- Increased Incidence of Neuroblastoma worldwide, innovations and the new product combinations are some of the important factors that are fueling the Neuroblastoma Market.
Neuroblastoma Pipeline Market Barriers
- However, lack of Awareness, drug-related side effects and other factors are creating obstacles in the Neuroblastoma Market growth.
Scope of Neuroblastoma Pipeline Drug Insight
- Coverage: Global
- Key Neuroblastoma Companies: ORIC Pharmaceuticals, Inc., Aum Bio, NanoPharmaceuticals, Athenex, Inc., Actuate Therapeutics Inc., PersonGen BioTherapeutics, KC Pharmaceuticals, Jubilant Pharmova Limited, Recombio, Clarity Pharmaceuticals, Eli Lilly and Company, Aptorum Group, and others
- Key Neuroblastoma Therapies: PLK4 Inhibitor Program, AUM302, BG-P-TAT, KUR-501, 9-ING-41, TAA06, DFMO (Eflornithine HCl), Iobenguane (131I), Racotumomab, 67Cu MeCOSar Octreotate, LY3295668, SACT 1, and others
- Neuroblastoma Therapeutic Assessment: Neuroblastoma current marketed and Neuroblastoma emerging therapies
- Neuroblastoma Market Dynamics: Neuroblastoma market drivers and Neuroblastoma market barriers
Request for Sample PDF Report for Neuroblastoma Pipeline Assessment and clinical trials
Table of Contents
1. Neuroblastoma Report Introduction
2. Neuroblastoma Executive Summary
3. Neuroblastoma Overview
4. Neuroblastoma- Analytical Perspective In-depth Commercial Assessment
5. Neuroblastoma Pipeline Therapeutics
6. Neuroblastoma Late Stage Products (Phase II/III)
7. Neuroblastoma Mid Stage Products (Phase II)
8. Neuroblastoma Early Stage Products (Phase I)
9. Neuroblastoma Preclinical Stage Products
10. Neuroblastoma Therapeutics Assessment
11. Neuroblastoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Neuroblastoma Key Companies
14. Neuroblastoma Key Products
15. Neuroblastoma Unmet Needs
16 . Neuroblastoma Market Drivers and Barriers
17. Neuroblastoma Future Perspectives and Conclusion
18. Neuroblastoma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
